Moderna's Coronavirus Vaccine Candidate 100% Effective at Preventing Severe COVID-19
On Monday morning, Moderna (NASDAQ: MRNA) released a highly encouraging primary efficacy analysis for its coronavirus vaccine candidate, mRNA-1273. The company also promised to submit a request for Emergency Use Authorization to the Food and Drug Administration by the end of the day.
With that efficacy analysis in hand, the FDA has scheduled an independent advisory committee meeting to publicly discuss the authorization request on Dec. 17. The FDA isn't obligated to follow the advice of the independent experts it meets with, but they usually land on the same page when it comes to interpreting clinical trial data.
Image source: Getty Images.
Source Fool.com
